APArnold C. Paulino

Arnold C. Paulino

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Arnold C. Paulino has a total of 34 co-authors. Here are the top co-authors by number of shared publications:

  • Bin S. Teh

    Department of Radiation Oncology, The Methodist Hospital, Houston, TX

    9 shared publications
  • Murali Chintagumpala

    Department of Pediatrics Texas Children's Cancer Center, Baylor College of Medicine Houston Texas

    4 shared publications
  • E. Brian Butler

    The Methodist Hospital and The Methodist Hospital Research Institute

    3 shared publications
  • Jack Su

    Department of Pediatrics Texas Children's Cancer Center, Baylor College of Medicine Houston Texas

    3 shared publications
  • M. Fatih Okcu

    Baylor College of Medicine, Houston, TX

    3 shared publications
  • Ali Mazloom

    Department of Radiation Oncology The Methodist Hospital and Weil‐Cornell Medical College Houston Texas

    2 shared publications

Latest Publications

  • Wilms and Other Pediatric Renal Tumors

    by Arnold C. Paulino, John Kalapurakal

  • Open Access

    Lymph node management in patients with paratesticular rhabdomyosarcoma

    by Nguyen D. Dang, Phuong‐Thanh Dang, Jason Samuelian, Arnold C. Paulino

    BACKGROUND: Paratesticular rhabdomyosarcoma (PTRMS) is the most common primary solid tumor arising from the mesenchymal tissue of the testis. Traditionally, retroperitoneal lymph node dissection is not recommended for children aged P < 0.01). Conversely, patients aged P = .37). The yield of positive lymph nodes was approximately ≥ 20% when < 11 lymph nodes were removed. The incidence of lymph node involvement was also higher in older patients compared with younger patients (40% vs 8%). Radiotherapy improved the OS rate in patients with lymph node involvement (5‐year OS rate: 90% with vs 36% without radiation; P < .0001).CONCLUSIONS: Lymph node dissection is recommended in patients aged ≥10 years. Radiotherapy is beneficial in patients with lymph node‐positive disease. Cancer 2013;119:3228–3233. © 2013 American Cancer Society.


  • Radiotherapy in Metastatic Ewing Sarcoma

    by Arnold C. Paulino, Wei Y. Mai, Bin S. Teh

    Objective: To review an institutional experience with radiotherapy (RT) in patients with metastatic Ewing sarcoma. Methods: Thirty patients with metastatic Ewing sarcoma were considered. Twenty-nine received multiagent chemotherapy, whereas 22 had local therapy, which included RT in 14, surgery in 5, and surgery followed by RT in 3. Results: The 5-year overall survival rate was 22.1%. On multivariate analysis, presence of uncommon sites of metastasis (brain, liver, spleen) (PP<0.001) were adverse factors for survival. Local control was not achieved in the 8 patients receiving only chemotherapy. All long-term survivors had local therapy including RT to metastatic bony sites and whole-lung irradiation for pulmonary metastasis. Conclusions: The presence of uncommon sites of metastasis confers a worse prognosis. Aggressive primary treatment including RT to metastatic sites should be considered in these patients.


  • Open Access

    Intensity‐modulated radiotherapy (IMRT) in pediatric low‐grade glioma

    by Arnold C. Paulino, Ali Mazloom, Keita Terashima, Jack Su, Adekunle M. Adesina, M. Faith Okcu, Bin S. Teh, Murali Chintagumpala

    BACKGROUND: The objective of this study was to evaluate local control and patterns of failure in pediatric patients with low‐grade glioma (LGG) who received treatment with intensity‐modulated radiation therapy (IMRT).METHODS: In total, 39 children received IMRT after incomplete resection or disease progression. Three methods of target delineation were used. The first was to delineate the gross tumor volume (GTV) and add a 1‐cm margin to create the clinical target volume (CTV) (Method 1; n = 19). The second was to add a 0.5‐cm margin around the GTV to create the CTV (Method 2; n = 6). The prescribed dose to the GTV was the same as dose to the CTV for both Methods 1 and 2 (median, 50.4 grays [Gy]). The final method was dose painting, in which a GTV was delineated with a second target volume (2TV) created by adding 1 cm to the GTV (Method 3; n = 14). Different doses were prescribed to the GTV (median, 50.4 Gy) and the 2TV (median, 41.4 Gy).RESULTS: The 8‐year progression‐free and overall survival rates were 78.2% and 93.7%, respectively. Seven failures occurred, all of which were local in the high‐dose (≥95%) region of the IMRT field. On multivariate analysis, age ≤5 years at time of IMRT had a detrimental impact on progression‐free survival.CONCLUSIONS: IMRT provided local control rates comparable to those provided by 2‐dimensional and 3‐dimensional radiotherapy. Margins ≥1 cm added to the GTV may not be necessary, because excellent local control was achieved by adding a 0.5‐cm margin (Method 2) and by dose painting (Method 3). Cancer 2013;119:2654–2659. © 2013 American Cancer Society.


  • Whole lung irradiation in pediatric patients using helical tomotherapy to minimize cardiac, breast, and thyroid dose

    by Farzan Siddiqui, Thomas Mathews, Bin S. Teh, John A. Kalapurakal, E. Brian Butler, Murali Chintagumpala, Arnold C. Paulino


  • Impact of PET‐CT on involved field radiotherapy design for pediatric Hodgkin lymphoma

    by Arnold C. Paulino, Judith Margolin, ZoAnn Dreyer, Bin S. Teh, Stephen Chiang

    Purpose To determine how the incorporation of PET-CT changes radiotherapy treatment in pediatric Hodgkin lymphoma. Procedure Fifty-three Hodgkin lymphoma patients with a median age of 14 years (6–21 years) underwent multiagent chemotherapy followed by involved field radiotherapy (IFRT) to initial sites of disease. All patients had conventional staging which included CT scan of the neck, chest, abdomen and pelvis, bone marrow biopsy ± MRI, Gallium scan and bone scan. All had an initial 18-F-fluoro-deoxy-D-glucose (FDG) PET-CT. When there was discordance between conventional staging and PET-CT staging, true sites of disease were determined either by biopsy or response to multiagent chemotherapy. Results In 19 of 53 (35.8%) patients, there was discordance between conventional staging and PET-CT findings. The most common location for the 23 sites of discordance were the spleen in 6 (26.1%), neck in 3 (13%), inguinal nodes in 3 (13%) and mediastinum in 3 (13%). A change in stage occurred in 5 (9.4%) as a result of PET-CT imaging. A change in IFRT fields occurred in 9 (17%); eight were more extensive while one was less extensive. For PET-CT, the specificity, sensitivity, positive predictive value and accuracy were 99.5%, 96.3%, 97.9%, and 98.9%. Conclusion Incorporation of PET-CT information was found to influence IFRT design in 17% of patients, with most having more extensive radiotherapy fields. Pediatr Blood Cancer 2012; 58: 860–864.


  • Characteristics and outcome of radiation and chemotherapy‐related mucoepidermoid carcinoma of the salivary glands

    by Jonathan Verma, Bin S. Teh, Arnold C. Paulino

    Background Mucoepidermoid carcinoma (MEC) of the salivary glands has been reported to occur in patients previously treated with chemotherapy and/or radiation. The purpose of our study is to review the patient, tumor, and treatment characteristics of patients who develop a treatment-related MEC. Procedure A PubMed search of English language articles was performed using the keywords and MeSH terms: mucoepidermoid, salivary gland, radiation-induced, second malignancy, radiotherapy, and chemotherapy. Results The search yielded 23 articles describing 58 patients who received chemotherapy and/or radiotherapy (RT) and subsequently developed MEC. The most common initial diagnoses were acute lymphoblastic leukemia (n = 18), acne (n = 9), and Hodgkin lymphoma (n = 6). Patients were divided into three groups according to chemotherapy and RT treatment: chemotherapy alone (n = 14), RT alone (n = 14), or chemotherapy and RT (n = 30). The parotid gland was the most common site for secondary MEC. Latent time (LT) to development of MEC from initial tumor treatment was significantly shorter in the patients treated with chemotherapy ± RT versus RT alone (7.9 years vs. 27.2 years, P < 0.01). The most common treatment for MEC was surgery alone followed by surgery and postoperative RT. The 2- and 5-year overall survival rates were 98% and 93.4% while the 2- and 5-year locoregional control rates were 97.7% and 92.5%, respectively. There was no difference in survival or locoregional control between groups exposed to RT alone, chemotherapy alone, or chemotherapy with RT for the initial tumor. Conclusion Radiation and chemotherapy-related MEC has an excellent prognosis. Pediatr Blood Cancer 2011; 57: 1137–1141.